Published in Chest on September 30, 2009
Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J (2015) 6.18
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med (2014) 1.58
Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis (2012) 1.40
Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health (2014) 1.15
Missed Opportunity to Prevent Tuberculosis. Am J Public Health (2015) 1.06
Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis (2010) 1.03
Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health (2012) 1.02
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect (2013) 0.98
Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS One (2012) 0.92
Tuberculosis knowledge, attitudes, and beliefs in foreign-born and US-born patients with latent tuberculosis infection. J Immigr Minor Health (2010) 0.92
Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis (2015) 0.90
Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. BMC Infect Dis (2014) 0.87
Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States. AIDS Patient Care STDS (2010) 0.84
Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis (2016) 0.84
Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PLoS One (2014) 0.83
Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect (2016) 0.82
A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC Public Health (2015) 0.82
Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis (2014) 0.82
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis (2015) 0.81
Eliminating tuberculosis one neighborhood at a time. Am J Public Health (2012) 0.81
Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. BMC Infect Dis (2014) 0.81
Tuberculosis among healthcare workers, United States, 1995-2007. Infect Control Hosp Epidemiol (2012) 0.80
Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep (2012) 0.80
Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis (2013) 0.80
Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis (2016) 0.79
Update on opportunistic infections in the era of effective antiretroviral therapy. Infect Dis Clin North Am (2014) 0.79
Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis (2013) 0.79
The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI). BMJ Open (2014) 0.78
Factors associated with noncompletion of latent tuberculosis infection treatment in an inner-city population in Edmonton, Alberta. Can J Infect Dis Med Microbiol (2014) 0.78
Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care (2012) 0.78
Enhanced Tuberculosis Infection Treatment Outcomes after Implementation of QuantiFERON®-Gold Testing. PLoS One (2015) 0.77
House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. BMC Public Health (2013) 0.77
Results of tuberculosis contact investigation in congregate settings in Korea, 2013. Osong Public Health Res Perspect (2014) 0.75
Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Med (2017) 0.75
Uptake and Acceptability of Information and Communication Technology in a Community-Based Cohort of People Who Inject Drugs: Implications for Mobile Health Interventions. JMIR Mhealth Uhealth (2015) 0.75
Tuberculosis preventive treatment in a single medical center and evaluation of the results. Exp Ther Med (2014) 0.75
Eliminating tuberculosis one neighborhood at a time. Am J Public Health (2014) 0.75
The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clin Rheumatol (2014) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Tuberculosis. Lancet (2003) 6.39
Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med (2004) 5.90
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Blood lead concentration and delayed puberty in girls. N Engl J Med (2003) 2.44
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med (2014) 2.29
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Motivations to donate blood: demographic comparisons. Transfusion (2002) 2.20
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis (2014) 2.03
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
Setting the agenda: a new model for collaborative tuberculosis epidemiologic research. Tuberculosis (Edinb) (2006) 1.77
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis (2008) 1.72
Attitudes toward blood donation incentives in the United States: implications for donor recruitment. Transfusion (2003) 1.70
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis (2007) 1.69
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med (2012) 1.63
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis (2003) 1.63
Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med (2014) 1.58
Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis (2009) 1.58
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr (2003) 1.55
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Epidemiology of tuberculosis in young children in the United States. Pediatrics (2014) 1.49
Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. Pediatr Infect Dis J (2015) 1.45
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis (2004) 1.36
Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res (2002) 1.35
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Determinants of return behavior: a comparison of current and lapsed donors. Transfusion (2007) 1.32
Behavioral and infectious disease risks in young blood donors: implications for recruitment. Transfusion (2003) 1.32
Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis (2010) 1.29
Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States. Am J Public Health (2015) 1.28
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis (2006) 1.21
Consensus guidelines for the safe prescription and administration of oral bowel-cleansing agents. Gut (2012) 1.20
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother (2009) 1.19
Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr (2011) 1.19
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents. Am J Clin Nutr (2002) 1.18
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis (2011) 1.16
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol (2009) 1.11
Tuberculosis contact investigation policies, practices, and challenges in 11 U.S. communities. J Public Health Manag Pract (2002) 1.11
Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr (2003) 1.11
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 1.09
Blood-donor perceptions of health history screening with a computer-assisted self-administered interview. Transfusion (2003) 1.07
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06
Rectus femoris transfer for children with cerebral palsy: long-term outcome. J Pediatr Orthop (2003) 1.06
Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. J Allergy Clin Immunol (2006) 1.04
A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood (2013) 1.03
Mitochondrial and ER-targeted eCALWY probes reveal high levels of free Zn2+. ACS Chem Biol (2014) 1.01
An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α. J Clin Endocrinol Metab (2013) 1.01
Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis (2013) 1.00
Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet (2010) 0.99
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol (2011) 0.98